# Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors

> **NCT04901806** · PHASE1 · TERMINATED · sponsor: **Pyramid Biosciences** · enrollment: 29 (actual)

## Conditions studied

- Solid Tumor, Adult
- Brain Tumor, Primary
- Desmoplastic Small Round Cell Tumor

## Interventions

- **DRUG:** PBI-200

## Key facts

- **NCT ID:** NCT04901806
- **Lead sponsor:** Pyramid Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-07-20
- **Primary completion:** 2023-07-26
- **Final completion:** 2023-07-26
- **Target enrollment:** 29 (ACTUAL)
- **Why stopped:** Sponsor terminated development of PBI-200
- **Last updated:** 2024-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04901806

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04901806, "Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT04901806. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*